Both the European Research Council (ERC) and COST contribute to the free flow of ideas and researchers in Europe, welcoming individuals regardless of their scientific field, career status, and country of origin. The ERC focuses on excellence, supporting both research and researchers, while COST plays a unique role as a bridge. It brings together excellent research projects and allows researchers and innovators to develop their ideas across various fields of science and technology by sharing them with their peers.
RepliCel Announces Record Year in Patents Granted
ACCESSWIRE
05 May 2021, 20:05 GMT+10
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies
VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020.
The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons.
RepliCel Life Sciences, Inc.: RepliCel Announces Record Year in Patents Granted
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies
VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020.
The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons.